FDA Clears Reverse Medical's MVP-5 Micro Vascular Plug for Peripheral Embolization

December 10, 2013—Reverse Medical Corporation (Irvine, CA) announced US Food and Drug Administration (FDA) clearance for the MVP-5, a micro vascular plug system for peripheral vessel embolization. The MVP-5 system is indicated for use to obstruct or reduce the rate of blood flow in the peripheral vasculature in vessels measuring between 3 and 5 mm.

The company also announced the first clinical case of the device in the United States. In the company’s press release, Rahul Patel, MD, commented, “Our first procedure with the MVP-5 was impressive and consistent with our prior experience with the MVP-3, resulting in accurate and immediate vessel occlusion upon deployment. The device tracked easily through tortuous anatomy, allowing for more precise control than conventional embolization coils. The MVP product line has become an essential device in my lab. I’m particularly excited for its utilization in my growing interventional oncology practice.” Dr. Patel is Assistant Professor of Interventional Radiology at Mount Sinai Hospital in New York, New York.

According to the company, the MVP micro vascular plug product line addresses a broad spectrum of peripheral vascular anatomy. The addition of the MVP-5 system will soon be followed by an MVP-7 and MVP-9. Clinical use of the company’s MVP-3 supported the development of these larger sizes as an alternative to treatment of vessel occlusion with embolization coils.